Navigation Links
DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease. Voyager has informed its shareholders that they have observed positive outcome trends among women, but no positive effect among men. DURECT has not independently verified the analysis performed or conclusions of Voyager. Based on these results, Voyager has stated that it intends to focus its efforts on developing Memryte for the treatment of Alzheimer's disease in women and on seeking a potential partner for the program.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit www.durect.com.

Forward-Looking Statement

The statements in this press release regarding Memryte, its potential performance and attributes, future development plans for Memryte and efforts by Voyager to seek a partner for the program are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Voyager's abilities to attract and reach business terms with a partner for the Memryte program, design, enroll, conduct and complete clinical trials, obtain successful results from such clinical trials, complete the design, developme
'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Medarex, Inc. (Nasdaq:, MEDX ) announced today ... non-fucosylated version of MDX-060 that targets CD30, a,marker ... malignant cells of,Hodgkin,s lymphoma (HL) as well as ... potency and efficacy in cell lines when,compared to ...
... TEL AVIV, Israel, December 8 InspireMD, Ltd. announced,that ... use in Israel,by the Israeli Ministry of Health. , ... system presents a novel combination of a coronary,stent merged ... by an expandable, flexible fishnet style, micron level knit,sleeve ...
Cached Medicine Technology:Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 3MGuard(TM) Coronary Stent System Approved in Israel 2MGuard(TM) Coronary Stent System Approved in Israel 3
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... the reason why isolated women are less vulnerable to falling ill ... ,The study is an eye-opener to the upcoming proof that ... a clue to the reason why socially isolated men are prone ... have shown a connection between stress and immune function. But this ...
... Bachoud-Lévi, M.D., and colleagues of the French national institute ... Huntington's disease// who previously received intracerebral fetal neural grafts ... ,But the same investigators reported today that ... years and then began to decline over the next ...
... at University of California have gained valuable insights about ... , a finding that may eventually accelerate current research ... is a joint effort by Dr. Frank Sauer (UCR ... Munich) and other researchers from University of California. The ...
... School of Public Health are one of the 14 ... Environmental Health Sciences// (NIEHS) to study the association between ... is a new study to control the rising obesity ... an individual’s body size. Working with various city departments, ...
... Research Institutes, Inc (NDRI) in New York City ... the role// of social supports, spirituality, religiousness, life ... recovery from addiction. The study reveals markedly improved ... a decrease in stress when people were inclined ...
... fear regarding the elevated risk of lymphoma associated with ... has found that such treatments may not confer an ... be seen in the latest issue of Arthritis & ... been found to increase with worsening of the chronic ...
Cached Medicine News:Health News:Women Portray Stronger Immune Response As Compared to Men, Study Suggests 2Health News:Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients 2Health News:Drug Addiction Recovery Buffered by Spirituality 2Health News:No Lymphoma Risk From Rheumatoid Arthritis Drugs 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
... cross action. Round handle. Divides nucleus for ... Nuclei of any hardness can be pre-chopped ... of pre-chopped nuclear fragments is rapid. Risk ... diminished. Shortened ultra sound time and minimal ...
1.5 mm inner cutting edge....
Nucleus chopper....
Medicine Products: